ASH: Differentiating Diagnosis and Treatment to Fit the Patient With Hemolytic Anemia: A Case-Based Approach

Friday, November 30, 2018
1:30PM-4:30PM
Lunch and registration: 12:30 PM – 1:30 PM

Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 10-13
Meeting Room: Grand Ballroom 10-13
333 W. Harbor Drive
San Diego, CA 92101

Overview:

Your management of patients with hematologic malignancy-induced anemias and other anemias, such as aplastic anemia, require careful diagnosis and classification of the underlying cause of symptoms. Your ability to distinguish between treatment-induced anemias, disease-related anemias, and anemias of genetic origin is essential before beginning treatment strategies. Often, you must determine whether treatment should address the anemia itself or its underlying cause. When managing myelodysplastic syndromes, pyruvate kinase deficiency (PKD), beta-thalassemia, aplastic anemia, and other hematologic disorders, the treatment of anemia is an essential aspect of patient care.

To help you optimize the management of your patients with hemolytic anemias, we have developed an exciting live satellite luncheon symposium, with interactive audience response system, a patient video, and live webcast to national remote audiences preceding the American Society of Hematology (ASH) 60th Annual Meeting, highlighting recent clinical advances in novel diagnostic, therapeutic, and patient counseling strategies to maximize treatment and management of your patients with hemolytic anemias. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion.

This activity features expert commentary and insights from renowned clinical educators who will contextualize data highlights and key findings through an innovative, engaging format, including a mix of didactic lectures, case studies that reflect challenges facing community hematologists when determining clinical trial options for patients, panel discussion, and Q&A. The program will give you the opportunity to reflect on best practices and your own clinical decisions to personalize care for your patients with hemolytic anemia.

Target Audience

This educational program is directed toward hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the diagnosis and treatment of patients with hemolytic anemias. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the diagnosis, treatment, and management of patients with hemolytic anemias are also invited to attend.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Explain the pathobiology and methods for differential diagnosis of patients with malignant and nonmalignant hematologic disorders
• Describe recent evidence concerning evolving treatment strategies to care for patients with hemolytic anemia, including benign and malignant hematologic disorders
• Incorporate methods to proactively mitigate the impact of adverse events resulting from treatment approaches for patients with benign or malignant hematologic disorder‒related anemia
• Apply recent evidence to inform clinical decision making to manage patients with hematologic malignancies and benign hemolytic anemia

Acknowledgment of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Bioverativ, A Sanofi Company, and Celgene Corporation.

Activity Chair

Rachael Grace, MD
Director, Hematology Clinic
Assistant Professor of Pediatrics
Harvard Medical School
Boston, MA